Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for NovaBay Pharmaceuticals (NBY) over the last 15 years, with Q3 2025 value amounting to $100.0 million.

  • NovaBay Pharmaceuticals' Other Non-Current Liabilities changed N/A to $100.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.0 million, marking a year-over-year change of. This contributed to the annual value of $334000.0 for FY2023, which is N/A changed from last year.
  • Latest data reveals that NovaBay Pharmaceuticals reported Other Non-Current Liabilities of $100.0 million as of Q3 2025.
  • NovaBay Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $100.0 million for Q2 2025, and its period low was $232000.0 during Q1 2024.
  • Its 5-year average for Other Non-Current Liabilities is $23.8 million, with a median of $900000.0 in 2025.
  • Examining YoY changes over the last 5 years, NovaBay Pharmaceuticals' Other Non-Current Liabilities showed a top increase of 28793.1% in 2025 and a maximum decrease of 28793.1% in 2025.
  • NovaBay Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $9.6 million in 2021, then tumbled by 70.42% to $2.8 million in 2022, then plummeted by 88.19% to $334000.0 in 2023, then tumbled by 30.54% to $232000.0 in 2024, then soared by 43003.45% to $100.0 million in 2025.
  • Its Other Non-Current Liabilities was $100.0 million in Q3 2025, compared to $100.0 million in Q2 2025 and $900000.0 in Q1 2025.